PKC-β抑制剂LY333531对糖尿病肾脏NADPH氧化酶与SOD蛋白表达的影响

首都医科大学学报 ›› 2011, Vol. 32 ›› Issue (3): 392-396.

PKC-β抑制剂LY333531对糖尿病肾脏NADPH氧化酶与SOD蛋白表达的影响

高霞¹，叶凤²，周赤燕²，刘慧敏³，徐援¹，夏正远^3，4，雷少青^3，4*

1. 首都医科大学附属北京朝阳医院内分泌科，北京 100020； 2. 武汉大学基础医学院生物化学与分子生物学教研室，武汉 430071； 3. 武汉大学人民医院麻醉科，武汉 430060； 4. 武汉大学基础医学院药理学教研室，武汉 430071

收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2011-06-21 发布日期:2011-06-21
通讯作者: 雷少青

Effects of protein kinase C-β inhibitor LY333531 on the protein expression of nicotinamide dinucleotide phosphate oxidase and superoxide dismutase in diabetic kidney

GAO Xia¹, YE Feng², ZHOU Chi-yan², LIU Hui-min³, XU Yuan¹, XIA Zheng-yuan^3,4, LEI Shao-qing^3,4*

1. Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China; 2. Department ofBiochemistry and Molecular Biology, School of Basic Medical Science, Wuhan University, Wuhan 430071, China; 3. Departmentof Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; 4. Department of Pharmacology, School ofBasic Medical Science, Wuhan University, Wuhan 430071, China

Received:1900-01-01 Revised:1900-01-01 Online:2011-06-21 Published:2011-06-21
Contact: LEI Shao-qing

摘要/Abstract

摘要：

目的研究蛋白激酶C（protein kinase，PKC）-β抑制剂LY333531对糖尿病肾脏尼克酰胺腺嘌呤二核苷酸磷酸（nicotinamide dinucleotide phosphate，NADPH）氧化酶与超氧化物歧化酶（superoxide dismutase，SOD）的影响。
方法 24只SD雄性大鼠（240~260 g），采用抽签法随机分为正常对照组（normal control，NC）、糖尿病组（diabetes mellitus，DM）及LY333531（LY）治疗组。LY组灌胃给予PKC-β抑制剂LY333531〔1 mg/(kg·d)〕治疗4周后测量血糖、肾质量/体质量、24 h 尿蛋白、内生肌酐清除率（creatinine clearance rate，Ccr）、游离15-F2tIsoprostane、总抗氧化浓度及SOD活性。Western blotting分析NADPH氧化酶亚基P22phox与P67phox，SOD亚型Cu/Zn-SOD与Mn-SOD蛋白改变。
结果与NC组比较，DM组血糖、肾质量/体质量、24 h尿蛋白、Ccr、血浆与肾脏中15-F2t-Isoprostane、血浆总抗氧化浓度及P22phox与P67phox表达明显增加，而肾脏总抗氧化物浓度、血浆与肾脏SOD活性、Cu/Zn-SOD及Mn-SOD蛋白表达明显减少（P<0.05）。LY333531除对血糖与Mn-SOD的表达无显著影响外，均能显著逆转上述变化。
结论 LY333531通过抑制糖尿病肾脏NADPH氧化酶的活化与表达，及促进Cu/Zn-SOD的表达而恢复SOD活性，以减少早期糖尿病肾脏的氧化损伤，从而发挥其保护肾脏作用。

关键词: 蛋白激酶C-&beta, 抑制剂, LY333531, 糖尿病性肾病, 尼克酰胺腺嘌呤二核苷酸氧化酶, 超氧化物歧化酶

Abstract:

Objective To study the effects of protein kinase C(PKC)-β inhibitor LY333531 on nicotinamide dinucleotide phosphate(NADPH) oxidase and superoxide dismutase(SOD) in diabetic kidney.
Methods Twenty-four male SD rats were randomly assigned to control group, diabetic group and diabetic with LY333531〔1 mg/(kg·d)〕 treatment group. After the treatment with LY333531 for four weeks, the levels of blood glucose, kidney weight/body weight, 24-hour urinary albumin, creatinine clearance rate(Ccr), free 15-F2t-Isoprostane, total antioxidant concentration and SOD activity were measured. The subunits P22phox and P67phox of NADPH oxidase, Cu/Zn-SOD and Mn-SOD protein expression were analyzed by Western blotting.
Results The levels of blood glucose, kidney weight/body weight, 24-hour urinary albumin, creatinine clearance rate, 15-F2t-Isoprostane in plasma and kidney, total antioxidant concentrations in plasma, the protein expression of P22phox and P67phox were all increased, but the levels of total antioxidant concentrations in kidney, SOD activity in plasma and kidney, Cu/Zn-SOD and Mn-SOD protein expression were significantly decreased in diabetic group as compared with control group(P<0.05). The treatment with LY333531 significantly prevented all these changes except for blood glucose and MnSOD protein expression.
Conclusion The PKC-β inhibitor LY333531 may protect early diabetic kidney from oxidative injury by inhibiting NADPH oxidase activation and expression, and restoring SOD activity by improving the expression of Cu/Zn-SOD subunit.

Key words: protein kinase C-&beta, inhibitor;LY333531;diabetic nephropathy;nicotinamide dinucleotide phosphate oxidase;superoxide dismutase

中图分类号:

R 587.1

高霞;叶凤;周赤燕;刘慧敏;徐援;夏正远;雷少青;. PKC-β抑制剂LY333531对糖尿病肾脏NADPH氧化酶与SOD蛋白表达的影响[J]. 首都医科大学学报, 2011, 32(3): 392-396.

GAO Xia;YE Feng;ZHOU Chi-yan;LIU Hui-min;XU Yuan;XIA Zheng-yuan;LEI Shao-qing;. Effects of protein kinase C-β inhibitor LY333531 on the protein expression of nicotinamide dinucleotide phosphate oxidase and superoxide dismutase in diabetic kidney[J]. Journal of Capital Medical University, 2011, 32(3): 392-396.

[1]	张雨, 董志翔, 李常城, 王丽, 杨敏福. 肥厚型心肌病¹⁸F-FAPI PET/CT显像的初步探索:与心脏磁共振比较[J]. 首都医科大学学报, 2022, 43(6): 845-853.
[2]	谭晓刚, 张毅. 新辅助免疫治疗在可切除非小细胞肺癌中的应用前景[J]. 首都医科大学学报, 2021, 42(5): 862-867.
[3]	孙熙木, 王华光, 赵昕, 吕少诚, 贺强, 刘丽宏. 肝移植患者术后巨细胞病毒感染的危险因素分析[J]. 首都医科大学学报, 2021, 42(4): 664-671.
[4]	孙梦雪, 王雷明, 滕梁红. 胶质瘤中BRAF基因异常的研究进展[J]. 首都医科大学学报, 2020, 41(3): 380-384.
[5]	陈峰, 郑晓红, 李文斌. 脑胶质瘤免疫治疗进展[J]. 首都医科大学学报, 2019, 40(6): 966-971.
[6]	刘全乐, 李天富, 王保国. 丙戊酸钠神经保护作用机制及其应用研究[J]. 首都医科大学学报, 2017, 38(3): 365-371.
[7]	汪晓磊, 马建民, 孟照洋, 尹奕, 王艳玲. 急性高眼压模型中p75^NTR抑制剂对视网膜神经节细胞作用的研究[J]. 首都医科大学学报, 2017, 38(1): 24-28.
[8]	张静爽, 马丽娜, 王蓉, 张景燕, 吴燕川, 赵志炜, 王玉兰. EX527对热量限制保护SH-SY5Y细胞的影响[J]. 首都医科大学学报, 2015, 36(5): 705-708.
[9]	张晶, 刘伟, 陈云雨, 司书毅. 以保罗样激酶1为靶点的抗肿瘤药物的筛选及活性评价[J]. 首都医科大学学报, 2014, 35(3): 337-343.
[10]	付文卓;吴英婷;张进禄. 吡咯烷类二肽基肽酶-Ⅳ抑制剂的最新研究进展[J]. 首都医科大学学报, 2012, 33(4): 538-543.
[11]	安立新;彭宇明;王保国;孙梅珍;袁芳. 停通气预处理对脑出血大鼠炎性介质和氧化物的影响[J]. 首都医科大学学报, 2009, 30(4): 547-551.
[12]	关键;王国干;朱俊. 直接凝血酶抑制剂及其临床应用[J]. 首都医科大学学报, 2007, 28(4): 462-466.
[13]	李卫萍;孙明;贾三庆. 阿托伐他汀对自发性高血压大鼠主动脉活性氧、p22phox表达和SOD活性的影响[J]. 首都医科大学学报, 2005, 26(2): 116-119.
[14]	孙丛晓;黄长胜;韩凤岳;刘娜;陈亚亮;杨琳. 中药复方髓伤平调节大鼠脑内自由基作用的研究[J]. 首都医科大学学报, 2004, 25(2): 147-149.
[15]	王旭东;樊峥;傅研;殷红;翟艳玲;祁雅慧;朱宇清;王瑾;赵相印. 2型糖尿病合并冠心病患者纤溶酶原激动抑制剂-1基因多态性分析[J]. 首都医科大学学报, 2004, 25(2): 223-226.